UFPTUFP TECHNOLOGIES INC
Surgical & Medical Instruments & Apparatus
- Revenue
- $603M
- 20% YoY
- Operating margin
- 15.3%
- 4.5% YoY
- EBITDA
- $111M
- 17% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 1.0×
- $108M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear135% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear1% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear29% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $206M | $354M | $400M | $504M | $603M | 20% |
| Operating income | $21M | $55M | $58M | $81M | $92M | 14% |
| Net income | $16M | $42M | $45M | $59M | $68M | 16% |
| Operating cash flow | $14M | $18M | $41M | $67M | $92M | 38% |
| Capex | $5M | $14M | $10M | $10M | — | |
| Stock-based comp | $2M | $3M | $5M | $7M | $9M | 29% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $8M | $8M | 476 | 113 |
| FY2024 | $5M | $9M | 525 | 113 |
| FY2023 | $5M | $8M | 369 | 102 |
| FY2022 | $4M | $7M | 253 | 83 |
| FY2021 | $3M | $4M | 151 | 104 |